化痰降浊方联合常规西药治疗痰浊痹阻证冠心病心绞痛临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:


Clinical Study on Huatan Jiangzhuo Prescription Combined with Routine Western Medicine for Angina Pectoris in Coronary Heart Disease with Turbid Phlegm Obstruction Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察化痰降浊方联合常规西药治疗痰浊痹阻证冠心病心绞痛的临床疗效。方法:选取痰浊痹阻证冠心病心绞痛患者 96 例,按随机数字表法分为对照组和观察组各 48 例。对照组给予常规西药治疗,观察组在对照组基础上给予化痰降浊方。比较 2 组治疗前后主症、次症评分和总分,观察血脂及血液流变学指标变化、临床效果及不良反应情况。结果:治疗后, 2 组主症、次症评分和总分较治疗前降低(P<0.05),且观察组均低于对照组(P<0.05)。治疗后,2 组甘油三酯(TG)、血清总胆固醇 (TC)、低密度脂蛋白胆固醇 (LDL-C) 及血浆黏度 (PV)、全血黏度 (WBV)、红细胞聚集指数 (AI) 及红细胞比容(HCT) 均较治疗前降低(P<0.05),且观察组各项指标均低于对照组(P<0.05)。治疗后,2 组高密度脂蛋白胆固醇(HDL-C)水平较治疗前升高,且观察组高于对照组 (P<0.05)。观察组总有效率为 89.58%,高于对照组 72.92%,差异有统计学意义(P<0.05)。观察组不良反应发生率为 14.58%,与对照组的 8.33%比较,差异无统计学意义 (P>0.05)。结论:化痰降浊方联合常规西药可有效减轻痰浊痹阻证冠心病心绞痛患者的症状,调节血脂及血液流变学指标,疗效较好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Huatan Jiangzhuo prescription combined with routine western medicine for angina pectoris in coronary heart disease with turbid phlegm obstruction syndrome. Methods:A total of 96 cases of patients with angina pectoris in coronary heart disease with turbid phlegm obstruction syndrome were divided into the control group and the observation group according to the random number table method,48 cases in each group. The control group was treated with routine western medicine,and the observation group was additionally treated with Huatan Jiangzhuo prescription based on the treatment of the control group. Before and after treatment, the scores of main and secondary symptoms and the total scores in the two groups were compared. The changes in indexes of blood lipid and hemorheology as well as clinical effect and adverse reactions were observed. Results:After treatment,the scores of main and secondary symptoms and the total scores in the two groups were decreased when compared with those before treatment(P<0.05), and the scores in the observation group were lower than those in the control group(P<0.05). After treatment,triglyceride (TG), serum total cholesterol(TC), low density lipoprotein cholesterol(LDL- C), plasma viscometry(PV), whole blood viscosity(WBV),erythrocyte aggregation index(AI) and hematocrit(HCT) in the two groups were decreased when compared with those before treatment(P<0.05),and the indexes in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of high-density lipoprotein cholesterol(HDL-C) in the two groups were increased when compared with those before treatment,and the one in the observation group was higher than that in the control group(P< 0.05). The total effective rate was 89.58% in the observation group,higher than that of 72.92% in the control group,the difference being significant(P<0.05). The incidence of adverse reactions was 14.58% in the observation group and 8.33% in the control group, there being no significance in the difference(P<0.05). Conclusion: Huatan Jiangzhuo prescription combined with routine western medicine can effectively relieve the symptoms of patients with angina pectoris in coronary heart disease with turbid phlegm obstruction syndrome and regulate the indexes of blood lipid and hemorheology with good curative effect.

    参考文献
    相似文献
    引证文献
引用本文

张荣珍.化痰降浊方联合常规西药治疗痰浊痹阻证冠心病心绞痛临床研究[J].新中医,2020,52(23):39-42

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-12-09
  • 出版日期:
文章二维码